



Correction to: Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use

Katherine A. Lyseng-Williamson¹

Published online: 12 October 2018
© Springer Nature Switzerland AG 2018

Correction to:
Drugs & Therapy Perspectives (2018) 34(9):411–419
<https://doi.org/10.1007/s40267-018-0539-6>

Page 416, column 2, from the beginning of the sentence on the last line to the end of the sentence on page 417, column 1, lines 1–4: the following text, which previously read:

“A 2-h duration of treatment was indicated by the significant ($p < 0.05$) improvements from baseline in Conners’ Adult ADHD Rating Scale Short-Version Self-Report scores at 4- and 12-h after administrations.”

Should read:

“A 12-h duration of treatment was indicated by the significant ($p < 0.05$) improvements from baseline in Conners’ Adult ADHD Rating Scale Short-Version Self-Report scores at 4- and 12-h after administration.”

The original article can be found online at <https://doi.org/10.1007/s40267-018-0539-6>.

✉ Katherine A. Lyseng-Williamson
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand